As of June 1, 2025, Orphazyme A/S (ORPHA.CO) reports a Net Margin of -1731.11%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of Orphazyme A/S's Net Margin
Over recent years, Orphazyme A/S's Net Margin has shown limited historical data. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2023-12-31 | -1731.11% |
| 2022-12-31 | -1731.11% |
This trend highlights how Orphazyme A/S manages its overall profitability and cost control over time.
Comparing Orphazyme A/S's Net Margin to Peers
To better understand Orphazyme A/S's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| Orphazyme A/S (ORPHA.CO) | -1731.11% |
| Nanobiotix SA (NANO.PA) | 586.89% |
| Bioventix PLC (BVXP.L) | 59.51% |
| Saniona AB (SANION.ST) | 56.39% |
| OSE Immunotherapeutics SA (OSE.PA) | 44.88% |
| Mabion SA (MAB.WA) | 27.21% |
Compared to its competitors, Orphazyme A/S's Net Margin is about average compared to peers, reflecting typical industry profitability.